Clinical Trial Update: Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating AZD0530 (saracatinib) in combination with carboplatin and paclitaxel has been withdrawn, with conditions including non-small cell lun…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• Saracatinib (AZD0530) (saracatinib)

Snippet

Sponsor: AstraZeneca | Conditions: Cancer, Non Small Cell Lung Cancer | Phase 1 | Status: WITHDRAWN